Our team recently found that, after DAU chemotherapy in acute lymphoblastic leukemia (ALL), serum Ankrd1 concentration decreased in patients with adverse cardiac events (ACE), but increased in patients without ACE, and the extent of Ankrd1 concentration changes was negatively correlated with the grade of ACE. The gene discussed is ANKRD1; the disease is acute lymphoblastic leukemia.